10 Hidden Penny Stocks to Buy Now

Page 9 of 9

1. Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX)

Upside Potential as of September 27, 2025: 579.61%

During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by a whopping 482.3%. Following the purchase of 239,751 shares, the global investment bank now owns 289,461 shares of the company’s stock, valued at approximately $741,000.

Investing in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is like planting a tree; with time and patience, it ought to grow. The biopharmaceutical company develops recombinant therapeutic proteins through its ProCellEx platform, while leveraging its expertise in rare genetic diseases.

What’s even more interesting is that Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is striving to expand ProCellEx into drug delivery optimization by aiming for particular tissue requirements. This step is what they call a “game-changer” since this system offers what traditional systems lack. From cost efficiency to expressing complex protein capabilities, this platform is poised to lead the future.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is a New Jersey-based biopharmaceutical company specializing in recombinant therapeutic proteins. With a commitment to developing innovative plant-based biologics, the company offers Elelyso, Elfabrio, PRX-115, and PRX-119.

While we acknowledge the potential of PLX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PLX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9